首页 | 本学科首页   官方微博 | 高级检索  
     


A new human prostate carcinoma cell line, 22Rv1
Authors:R. Michael Sramkoski  Thomas G. Pretlow II  Joseph M. Giaconia  Theresa P. Pretlow  Stuart Schwartz  Man-Sun Sy  Susan R. Marengo  Johng S. Rhim  Desheng Zhang  James W. Jacobberger
Affiliation:(1) Cancer Research Center, Case Western Reserve University, 10900 Euclid Avenue, 44106-4944 Cleveland, Ohio;(2) Department of Genetics, Case Western Reserve University, 44106 Cleveland, Ohio;(3) Department of Pathology, Case Western Reserve University, 44106 Cleveland, Ohio;(4) Department of Urology, Case Western Reserve University, 44106 Cleveland, Ohio;(5) Laboratory of Biochemical Physiology, National Cancer Institute, 21702 Frederick, Maryland
Abstract:Summary A cell line has been derived from a human prostatic carcinoma xenograft, CWR22R. This represents one of very few available cell lines representative of this disease. The cell line is derived from a xenograft that was serially propagated in mice after castration-induced regression and relapse of the parental, androgen-dependent CWR22 xenograft. Flow cytometric and cytogenetic analysis showed that this cell line represents one hyper DNA-diploid stem line with two clonal, evolved cytogenetic sublines. The basic karyotype is close to that of the grandparent xenograft, CWR22, and is relatively simple with 50 chromosomes. In nude mice, the line forms tumors with morphology similar to that of the xenografts, and like the parental CWR22 and CWR22R xenografts, this cell line expresses prostate specific antigen. Growth is weakly stimulated by dihydroxytestosterone and lysates are immunoreactive with androgen receptor antibody by Western blot analysis. Growth is stimulated by epidermal growth factor but is not inhibited by transforming growth factor-β1.
Keywords:cancer  epithelial cell  xenograft  androgen response  cell growth  EGF  TGF-β  
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号